Regulating the regulator: negative regulation of Cbl ubiquitin ligases

被引:78
作者
Ryan, PE
Davies, GC
Nau, MM
Lipkowitz, S
机构
[1] NCI, Cellular & Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] George Washington Univ, Inst Biomed Sci, Washington, DC 20037 USA
关键词
D O I
10.1016/j.tibs.2005.12.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cbl proteins are regulators of signal transduction through many pathways and, consequently, regulate cell function and development. They are ubiquitin ligases that ubiquitinate and target many signaling molecules for degradation. The Cbl proteins themselves are regulated by an increasingly complex network of interactions that fine-tune the effects that Cbl proteins have on signaling. The negative regulation of Cbl protein function can occur via cis-acting structural elements that prevent inappropriate ubiquitin ligase activity, degradation of the Cbl proteins, inhibition without degradation owing to interaction with other signaling proteins, deubiquitination of Cbl substrates, and regulation of assembly of the endosomal ESCRT-I complex. Defects in the regulatory mechanisms that control Cbl function are implicated in the development of immunological and malignant diseases.
引用
收藏
页码:79 / 88
页数:10
相关论文
共 102 条
[1]   Overexpression of βPix-a in human breast cancer tissues [J].
Ahn, SJ ;
Chung, KW ;
Lee, RA ;
Park, IA ;
Lee, SH ;
Park, DE ;
Noh, DY .
CANCER LETTERS, 2003, 193 (01) :99-107
[2]   Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination [J].
Alwan, HAJ ;
van Zoelen, EJJ ;
van Leeuwen, JEM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (37) :35781-35790
[3]   Tal, a Tsg101-specific E3 ubiquitin ligase, regulates receptor endocytosis and retrovirus budding [J].
Amit, I ;
Yakir, L ;
Katz, M ;
Zwang, Y ;
Marmor, MD ;
Citri, A ;
Shtiegman, K ;
Alroy, I ;
Tuvia, S ;
Reiss, Y ;
Roubini, E ;
Cohen, M ;
Wides, R ;
Bacharach, E ;
Schubert, U ;
Yarden, Y .
GENES & DEVELOPMENT, 2004, 18 (14) :1737-1752
[4]   TUMOR-INDUCTION BY ACTIVATED ABL INVOLVES TYROSINE PHOSPHORYLATION OF THE PRODUCT OF THE CBL ONCOGENE [J].
ANDONIOU, CE ;
THIEN, CBF ;
LANGDON, WY .
EMBO JOURNAL, 1994, 13 (19) :4515-4523
[5]   Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b [J].
Bachmaier, K ;
Krawczyk, C ;
Kozieradzki, I ;
Kong, YY ;
Sasaki, T ;
Oliveira-dos-Santos, A ;
Mariathasan, S ;
Bouchard, D ;
Wakeham, A ;
Itie, A ;
Le, J ;
Ohashi, PS ;
Sarosi, I ;
Nishina, H ;
Lipkowitz, S ;
Penninger, JM .
NATURE, 2000, 403 (6766) :211-216
[6]   FMS MUTATIONS IN PATIENTS FOLLOWING CYTOTOXIC THERAPY FOR LYMPHOMA [J].
BAKER, A ;
CACHIA, P ;
RIDGE, S ;
MCGLYNN, H ;
CLARKE, R ;
WHITTAKER, J ;
JACOBS, A ;
PADUA, RA .
LEUKEMIA RESEARCH, 1995, 19 (05) :309-318
[7]   Src promotes destruction of c-Cbl: Implications for oncogenic synergy between Src and growth factor receptors [J].
Bao, J ;
Gur, G ;
Yarden, Y .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (05) :2438-2443
[8]   CBLB variants in type 1 diabetes and their genetic interaction with CTLA4 [J].
Bergholdt, R ;
Taxvig, C ;
Eising, S ;
Nerup, J ;
Pociot, F .
JOURNAL OF LEUKOCYTE BIOLOGY, 2005, 77 (04) :579-585
[9]   Isolation and characterization of a novel, transforming allele of the c-Cbl proto-oncogene from a murine macrophage cell line [J].
Bisson, SA ;
Ujack, EE ;
Robbins, SM .
ONCOGENE, 2002, 21 (23) :3677-3687
[10]  
BLAKE TJ, 1991, ONCOGENE, V6, P653